Lung transplantation (LTx) has become the gold standard treatment for end-stage
respiratory failure. Recently, extended lung donor criteria have been applied to decrease the …

Lung transplantation is often the only viable treatment option for a patient with end-stage
lung disease. Lung transplant results have improved substantially over time, but ischemia …

BACKGROUND The application of mesenchymal stromal cell (MSC)–based therapy during
ex vivo lung perfusion (EVLP) could repair injured donor lungs before transplantation. The …

Mesenchymal stem or stromal cells (MSCs) are multipotent cells that play a pivotal role in
various phases of lung development and lung homeostasis, and potentially also lung …

While multipotent mesenchymal stromal cells have been recently isolated from adult lung (L-
MSCs), there is very limited data on their biological properties and therapeutic potential in …

Lung transplantation is the only therapeutic option for end-stage pulmonary failure.
Nevertheless, the shortage of donor pool available for transplantation does not allow to …

All adult tissues, including the lung, have some capacity to self‐repair or regenerate through
the replication and differentiation of stem cells resident within these organs. While lung …

Chronic lung transplant rejection (termed chronic lung allograft dysfunction [CLAD]) is the
main impediment to long-term survival after lung transplantation. Bone marrow-derived …

Multipotent mesenchymal stem/stromal cells (MSCs) possess robust self-renewal
characteristics and the ability to differentiate into tissue-specific cells. Their therapeutic …

Mesenchymal stromal/stem cells (MSCs) are a fibroblast-like cell population with high
regenerative potential that can be isolated from many different tissues. Several data suggest …